Kornimate/medical-research-clean huggingface dataset:
myofascial pain syndrome and plantar fasciitis treatment

Conditions: Plantar Fascitis; Myofascial Pain Syndrome

Summary: patients with plantar fasciitis between the ages of 25-65 years who presented to the physical medicine and rehabilitation clinic with the complaint of heel pain and met the inclusion and exclusion criteria will be included in the study. demographic data (age, gender, body mass index, symptom duration) will be recorded at the beginning of the study. then, foot functional index (ffi) and visual analog scale (vas) scales will be recorded. participants will be randomly divided into two groups. group 1 will receive dry needling and group 2 will receive extracorporeal shock wave therapy (eswt). patients in the 1st group will undergo 3 sessions of dry needling with seirin branded 0.6\*50 mm acupuncture needles at one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles. patients in the 2nd group, patients in this group received three sessions of eswt (masterplus mp 200 energy 2 trademarked eswt device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 hz for three weeks, each session once a week. each of the five most sensitive and painful points was given 400 pulses in the supine position


Eligibility criteria:
inclusion criteria: * patients aged 25-65 years with heel pain for more than 6 weeks * tenderness on palpation in the medial calcaneal region * aggravation of symptoms while standing and in the first hours of the morning * who agreed not to receive anti-inflammatory treatment during the study period * fascia thickness \>4mm measured by ultrasound. exclusion criteria: * patients diagnosed with rheumatologic diseases * those diagnosed with diabetes mellitus (dm), those with chronic liver and kidney failure * anti-inflammatory-analgesic treatment within the last 1 month * diagnosed with inflammatory rheumatic disease * those with a history of foot surgery * those with mid or hindfoot deformity * previous history of central or peripheral nerve damage, lower extremity neuropathy * those diagnosed with diabetes mellitus * those with cognitive impairment * unassisted mobilization * those with bleeding disorders * pregnant women

Keywords: plantar fasciitis eswt dry needling
development of molecular diagnostic platform for tuberculosis

Conditions: Tuberculosis

Summary: this study evaluates new technique for diagnosis of tuberculosis. among patients who are suspected with tuberculosis, participants will be tested conventional method including xpert tb/rif assay, and new diagnostic technique using homobifunctionalimidoesters compounds.


Eligibility criteria:
inclusion criteria: * patients who are suspected with pulmonary tuberculosis, tuberculosis meningitis, tuberculosis peritonitis, tuberculosis pleurisy exclusion criteria: * under 18 years
surgical management of optic disc pit maculaopathy

Conditions: Optic Disc Structural Anomaly; Maculopathy

Summary: to evaluate the anatomical and functional results of pars plana vitrectomy (ppv) combined with internal limiting membrane (ilm) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (odp) maculopathy.

as it is well known, optic disc pit (odp) is a rare congenital disease which is usually associated with maculopathy (odp-m) in the form of intraretinal and subretinal fluid accumulation at the macular area leading to visual impairment. with no definite treatment and absence of guidelines for its management, the invistigators considered their prospective, interventional case series to evaluate the anatomical and functional results of pars plana vitrectomy (ppv) combined with internal limiting membrane (ilm) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (odp) maculopathy.

Eligibility criteria:
inclusion criteria: * patients included in this study are those with odp associated with macular detachment exclusion criteria: * exclusion criteria included patients unfit for general anesthesia, those with insufficient clear media to perform the surgery with ilm peeling and those with other ocular diseases that can affect central macular thickness (cmt) and the best corrected visual acuity (bcva).

Keywords: optic disc pit retinal detachment maculopathy
efficacy study of travoprost aps versus travatan

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: a multi-center double-masked study of the safety and efficacy of travoprost aps compared to travatan in patients with open-angle glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * 18 years of age or older, either gender and any race. * open angle glaucoma (oag) or ocular hypertension (oht). * not currently on any iop-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and iop-lowering monotherapy. * all patients: mean iop in same eye (at both eligibility 1 \& 2 visits): ≥ 24 and ≤ 36 mmhg at 9 am; and ≥ 21 and ≤ 36 mmhg at 11 am \& 4 pm. * other protocol-defined inclusion criteria may apply. exclusion criteria: * females of childbearing potential not meeting conditions set in the protocol. * severe central visual field loss. * angle shaffer grade \< 2. * cup/disc ratio \> 0.8 (horizontal or vertical measurement). * best corrected visual acuity (va) score worse than 55 etdrs letters read (equivalent to approximately 20/80 snellen or 0.25 decimal). * intraocular surgery or trauma within last 6 months. * any abnormality preventing reliable applanation tonometry. * history of or current ocular pathology (including severe dry eye) that would affect the conduct of the study. * allergy/hypersensitivity to study medications. * unable to discontinue use of all iop-lowering medications for a minimum wash-out period of 5 to 28 days prior to the eligibility visit. * less than 30 days stable dosing regimen of medications used on a chronic basis that may affect iop. * use of any additional topical or systemic ocular hypotensive medication during the study. * therapy with another investigational agent within 30 days prior to the screening visit. * other protocol-defined exclusion criteria may apply.

Keywords: oag oht
evaluation of loratadine for prevention of pegfilgrastim-induced pain

Conditions: Pegfilgrastim-induced Back and Leg Pain

Summary: the purpose of this study is to determine the incidence of pegfilgrastim-induced back and leg pain and to determine whether the antihistamine loratadine can prevent pegfilgrastim-induced back and leg pain.

pegfilgrastim is a myeloid growth factor that stimulates neutrophil precursors and can be used to decrease infection risk associated with neutropenia. however pegfilgrastim may induce back and leg pain in 20-50% of patients. no intervention has been consistently successful in treating or preventing this pain. the exact mechanism of pegfilgrastim-induced pain is unknown but may be related to histamine-mediated inflammation. several case reports and anecdotal reports have suggested efficacy of antihistamines for this indication. this study will have two parts. in the first part (observational phase), patients receiving pegfilgrastim will be surveyed to document the incidence of significant pegfilgrastim-induced back and leg pain. in the second part (treatment phase), patients who previously experienced such pain will be randomized to receive a 7-day course of either the antihistamine loratadine or placebo to determine whether pegfilgrastim-induced back and leg pain can be prevented with this intervention.

Eligibility criteria:
inclusion criteria: * histologic or cytologic evidence of malignancy * scheduled to receive pegfilgrastim with two consecutive cycles of similar chemotherapy with at least a 14 day interval between cycles * adequate renal function: estimated creatinine clearance \> 30 ml/min * adequate hepatic function: ast, alt, total bilirubin \<= 2.5 x uln * age \>= 18 years * performance status 0-3 * able to read and understand english * signed informed consent exclusion criteria: * history of hypersensitivity or intolerance to antihistamines * concurrent use of antihistamines other than study medications during or for 2 days prior to the study period except for a single dose of antihistamine as required for administration of chemotherapy or blood transfusion * concomitant use of amiodarone * previous use of pegfilgrastim or filgrastim

Keywords: pegfilgrastim loratadine myalgia/arthralgia
3d transcranial ultrasound brain imaging (3d-trubi) instrument for point-of-care diagnosis of intracranial hemorrhages

Conditions: Traumatic Brain Hemorrhage; Traumatic Brain Injury; Intracranial Hemorrhages; Ultrasound Exams; 3D SONOGRAPHY

Summary: the primary objective of this study is to assess the safety of the 3d transcranial ultrasound brain imaging (3d trubi) device in traumatic brain injury (tbi) patients with intracranial hemorrhage (ich). the secondary objective is to assess the diagnostic potential of 3d trubi. the latter will be achieved by comparison of 3d trubi scans with admission head computed tomography (ct), the standard of care diagnostic modality. demonstrating the feasibility and safety of the 3d trubi system is the first step toward expanding access of an alternative to ct for diagnostic imaging and triage of mass casualties of war or natural disasters in the field and in rapidly deployed medical centers or other austere environments.

eligible participants positive for intracranial hemorrhage (ich) due to traumatic brain injury (tbi) will undergo a full scanning procedure by trained investigators. examination with the 3d trubi system will involve acquisition of 16 pre-defined bilateral head points. the total time to complete the procedure is approximately 20 minutes. during the examination, feasibility and safety metrics will be collected. additional injury data will be reviewed from participants' electronic medical record. the goal of the study is 1) to evaluate the safety of the 3d trubi device in the target population and 2) do demonstrate the feasibility of the device to detect ich compared to standard medical imaging.

Eligibility criteria:
inclusion criteria: * age 18-89 * acute head injury with ct-confirmed intracranial hemorrhage * able to obtain written, informed consent from participant or legally authorized representative * able to receive intervention within 4 hours of admission head ct * able to feasibly receive intervention prior to neurosurgical indication exclusion criteria: * did not receive routine head ct * prisoner or wards of state * large or open skull wounds prohibiting ultrasound acquisition * received large volume fluid resuscitation (e.g. \>3 units of blood product) within 2 hours of intervention * any prohibiting condition or contraindication for ultrasound image acquisition

Keywords: transcranial ultrasound traumatic brain injury intracranial hemorrhage ultrasound
treatment of dupuytren's contracture with collagenase clostridium histolyticum injection (xiapex)

Conditions: Dupuytren's Contracture

Summary: this study will evaluate the impact of xiapex treatment on the range of motion (rom) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to rom. recovery to normal activities, recovery time (how long overall, time to use hand, time to return to work or daily activities, amount of work or daily activity time missed or reduced and affects on productivity and daily activities) will be assessed via patient diary. use of concomitant analgesic medications will be recorded and total healthcare resource utilization (hcru).


Eligibility criteria:
inclusion criteria: * presenting with a dupuytren's contracture of at least 20 degrees caused by a palpable cord in at least one finger other than the thumb. * positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top. exclusion criteria: * received a treatment on the selected joint, within 90 days of enrollment in the study, for dupuytren's contracture including needle aponeurotomy or any surgical procedure * on anticoagulant medication or has received anticoagulant medication (except aspirin less than 150 mg daily) within 7 days before the first injection * has a chronic muscular, neurological, or neuromuscular disorder that affects the hands

Keywords: dupuytren's treatment injection recovery health care resources
effects of drugs on responses to brain and emotional processes

Conditions: Autism Spectrum Disorder; Healthy

Summary: to study the effects of a psychostimulant on responses to affective touch in individuals with a range of autistic traits


Eligibility criteria:
inclusion criteria: * bmi between 19 and 30 (no one under 130 lbs) * smokers smoking less than 25 cigarettes per week * have used ecstasy no more than 40 times with no adverse responses. exclusion criteria: * high blood pressure * any medical condition requiring regular medication * individuals with a current (within the last year) dsm-iv axis 1 diagnosis * individuals with a history of dependence on stimulant drugs. * women who are pregnant or trying to become pregnant
effect of oral 5-htp intake on urinary 5-hiaa excretion

Conditions: Carcinoid Tumors; Neuroendocrine Tumors

Summary: this is a research study looking at the effect of 5-hydroxy tryptophan (5-htp) on urine excretion of 5-hydroxyindolacetic acid (5-hiaa). 5-htp is a common over the counter product that is sold in natural food stores and via the internet. increased levels of 5-hiaa in the urine can be found in a specific type of cancer, called carcinoid tumor. this study will examine the effect of oral 5-htp intake on 5-hiaa excretion. understanding this effect may help to determine which tests should be done in a patient with increased 5-hiaa excretion who's also taking 5-htp.

5-htp is a common over the counter product that is sold in natural food stores and via the internet. it is claimed to improve sleep problems, depression, anxiety, compulsive disorders, restless leg syndrome, migraines, fibromyalgia, and low pain threshold.increased levels of 5-hiaa in the urine can be a of a specific type of cancer, called carcinoid tumor. urinary 5-hiaa levels can also be increased by a number of food products and drugs. oral 5-htp is not known as a cause of elevation of 5-hiaa in urine. however, recent information suggests that 5-htp may cause an increase. in this study we examine the effect of oral 5-htp intake (100 mg at bedtime for 10 days) on 5-hiaa excretion in the urine, following a prospective, double-blind placebo-controlled study design. understanding this effect may help to determine which tests should be done in a patient with increased 5-hiaa excretion who's also taking 5-htp.

Eligibility criteria:
inclusion criteria: * 18 years and older * in good health exclusion criteria: * pregnancy * intake of drugs that affect 5-hiaa excretion in urine * anti-depressants * participation in other studies

Keywords: 5hydroxytryptamine chromogranin a 5hiaa carcinoid
implementation of a new motor skill learning therapeutic device in children with cerebral palsy rehabilitation

Conditions: Cerebral Palsy

Summary: study of the efficiency of a new interactive interface to apply all the therapeutic principles of motor skill learning used in high dosage intensive interventions. investigation of its effects on motor, functional and neuroplastic changes in children after high and low dosage intensive interventions using or not the interface.


Eligibility criteria:
inclusion criteria: * diagnosis of unilateral cerebral palsy * macs level i, ii or iii * gmfcs level i, ii, iii exclusion criteria: * unstable seizure * cognitive deficit that prevent understanding of simple games * botulinic toxin injection, surgery, or another unusual intervention in the 6 months preceding the study and for the duration of the study

Keywords: motor function motor skill learning
a study to evaluate the safety, tolerability, kinetics, biodistribution and repeatability of 11c-bms-986196 after intravenous (iv) administration in healthy participants and after repeat iv administration in participants with multiple sclerosis

Conditions: Multiple Sclerosis (MS)

Summary: the purpose of this study is to evaluate the safety, tolerability, kinetics, biodistribution and central nervous system signal of 11c-bms-986196 after intravenous (iv) administration in healthy participants and after repeat iv administration in participants with multiple sclerosis.


Eligibility criteria:
inclusion criteria: for parts a \& b: * body mass index (bmi) of 18 to 34 kg/m2, inclusive, and total body weight ≥ 50 kg * documentation of normal allen's test result at screening and on pet scanning days in the arm that will be used for arterial line placement for part a only: • healthy male and female participants without clinically significant deviation from normal in medical history, physical examination (pe), electrocardiograms (ecgs), and clinical laboratory determinations for part b only: * male or female participant diagnosed with ms according to the 2017 revisions of the mcdonald diagnostic criteria * expanded disability status scale (edss) score between 0 to 6.5, inclusive, at screening exclusion criteria: for parts a \& b: * benign ms defined as a baseline edss of 2.0 with ms diagnosis ≥ 10 years prior to day 1. spinal ms without clinical or radiological evidence of brain lesions. any other combination of clinical and radiological data suggestive of an absence of inflammatory brain lesions. * any major surgery within 4 weeks of study treatment administration and/or any minor surgery within 2 weeks of tracer administration for part a only: • any significant acute or chronic medical illness for part b only: * any significant acute or chronic medical illness (other than ms) posing a risk to the participant's safety or negatively affecting the ability to detect cns pet signal * ms relapse within 14 days prior to day 1. participants with a ms relapse within 30 days prior to day 1 must agree to have their second pet scan scheduled on day 1 or day 2 other protocol-defined inclusion/exclusion criteria apply

Keywords: multiple sclerosis (ms) healthy participants 11c-bms-986196 pet tracer
the effectiveness of pharmacist-led educational model in patients with allergic rhinitis

Conditions: Allergic Rhinitis; Pharmaceutical Care; Pharmaceutical Services

Summary: allergic rhinitis is a chronic respiratory disorder affecting patients' quality of life and work performance. pharmacists are identified as suitable professionals to deliver patient education and pharmaceutical care in managing allergic rhinitis (ar) patients. local clinical practice guidelines in malaysia are lacking, especially in pharmaceutical care in public healthcare institutions. this study protocol describes a randomised control trial (rct) that aims to determine the effectiveness of a pharmacist-led educational model in managing ar (ar-prise model) compared to standard pharmaceutical care. the ar-prise model delivers patient educational material (video) and an algorithm for pharmaceutical care.

this is a six-month, single-centre, prospective, randomised, two-arm, and parallel-group controlled trial. this trial recruits patients attending a tertiary hospital's otorhinolaryngology outpatient clinics. the participants are randomised into the control or intervention groups at 1:1 using permuted block randomisation. each group required 77 participants. the control group will receive standard pharmaceutical care. the intervention group will receive pharmacist-led education according to the ar-prise model. both groups will be assessed for the middle turbinate endoscopy findings, disease severity, knowledge level, symptom control, medication adherence, and quality of life (qol) at baseline and end-of-study follow-up (day 180±7). depending on the feasibility at day 60±7 and 120±7, they will be followed up virtually or face-to-face. during the intermediate follow-up, the participants will be assessed for symptom control, medication adherence, and qol. the intention-to-treat analysis will include all participants assigned to each group. an independent t-test compares the mean difference in knowledge level between the two groups. a two-way repeated measure anova analysis will be employed to determine between-group differences for scores of symptom control, adherence rate, and qol. a one-way repeated measure anova will be performed for within-group analysis. a p-value \< 0.05 is considered statistically significant.

Eligibility criteria:
inclusion criteria: * inclusion criteria for patients include an aged 18 to 80, malaysian, diagnosed with allergic rhinitis, and capable of reading and writing in english or malay, who attend the otorhinolaryngology outpatient clinic at raja permaisuri bainun hospital. exclusion criteria: * patients who are pregnant, lactating, or have a comorbid diagnosis of chronic rhinosinusitis will be excluded. * patients having psychiatric problems, dementia, terminal illnesses, comorbidities, post-covid-19 conditions with symptoms that continue beyond 3 months after being infected will be excluded.

Keywords: allergic rhinitis pharmacist education pharmaceutical services
study of su011248 in combination with docetaxel (taxotere) and prednisone in patients with prostate cancer

Conditions: Prostatic Neoplasms

Summary: this is a multi-center, open-label, phase 1/2 study of su011248 (sunitinib malate, sutent) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mhrpc).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate * patients must have progressive hormone-refractory prostate cancer (hrpc): patients must have undergone primary hormone treatment (e.g. orchiectomy or gonadotropin releasing hormone analog with or without antiandrogens). for patients who received antiandrogen therapy, disease progression must have been determined after antiandrogen discontinuation * progressive disease based on either non-measurable disease and an elevated psa or measurable disease * eastern cooperative oncology group (ecog) performance status 0 or 1 exclusion criteria: * prior thalidomide, anti-vascular endothelial growth factor (vegf) therapy, vegf receptor inhibitor, platelet-derived growth factor (pdgf) receptor inhibitor or anti-angiogenic treatment of any kind including investigational therapy * prior chemotherapy * uncontrolled pain at baseline, impending complication from bone metastasis (fracture and/or compression) and/or presence of urinary obstruction (urinary retention, hydronephrosis) * history of cardiac dysfunction, qt interval corrected for heart rate (qtc) \>450 msec * central nervous system (cns) involvement

Keywords: first-line treatment of metastatic hormone-refractory prostate cancer sutent in combination with docetaxel and prednisone